["alzheimer's disease"]
['idalopirdine 60 mg']

        Inclusion Criteria:

          -  the patient has completed Visit 7 (Completion Visit) in the lead-in double-blind,
             placebo controlled clinical studies 14861A/NCT01955161 or 14862A/NCT02006641

        For patients in the OLEX-MEM:

          -  The patient has completed Visit 6 (Week 28) of the OLEX.

          -  The patient, according to the judgement of the investigator, requires initiation of
             treatment with memantine as per local label/SmPC/treatment guidelines.

        Exclusion Criteria:

          -  The patient has a moderate or severe ongoing adverse event from the lead-in study
             considered a potential safety risk by the investigator.

          -  The patient has experienced seizures before Completion Visit in the lead-in study.

          -  The patient has evidence of clinically significant disease.

          -  The patient's donepezil treatment is likely to be interrupted or discontinued during
             the study.

          -  The patient is receiving therapy with another acetylcholinesterase inhibitors (AChEI).

        Other protocol-defined inclusion and exclusion criteria may apply.
      